 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Michael R. Hayden | |
|---|---|
 | |
| Born | 1951 (age 72–73) |
| Alma mater | Harvard University University of Cape Town |
| Awards | Humanitarian Award (2020) Inductee, Canadian Medical Hall of Fame (2017) Gairdner Foundation Wightman Award (2011) Order of Canada (2010) Order of British Columbia (2009) Canada's Health Researcher of the Year - Biomedical and Clinical Research, Canadian Institutes for Health Research CIHR (2008) |
| Scientific career | |
| Fields | Medical genetics, human genetics, personalized medicine |
| Institutions | Centre for Molecular Medicine and Therapeutics, Child & Family Research Institute, University of British Columbia British Columbia's Children's Hospital British Columbia's Children's Hospital Provincial Health Services Authority |
Michael R. Hayden, CM OBC FRSC[1] (born 1951)[1] is a Killam Professor of Medical Genetics at the University of British Columbia, the highest honour UBC can confer on any faculty member.[citation needed] Only four such awards have ever been conferred in the Faculty of Medicine.[citation needed] Dr. Hayden is also Canada Research Chair in Human Genetics and Molecular Medicine. Hayden is best known for his research in Huntington disease (HD).
He is a senior scientist and former director of the Centre for Molecular Medicine and Therapeutics (CMMT) in Vancouver, British Columbia, Canada; a genetic research centre within UBC's Faculty of Medicine and affiliated with the BC Children's Hospital Research Institute and the BC Children's Hospital Foundation, which he founded. He was also the Program Director of the Translational Laboratory in Genetic Medicine in Singapore from 2011 to 2020, and was appointed as the President of Global R&D and Chief Scientific Officer at Teva Pharmaceutical Industries from 2012 to 2017.[2][3] During this time, approximately 35 new products were approved in major markets with many for diseases of the central nervous system and led the approval of Austedo for chorea in HD, the second drug ever to be approved for HD. In 2015, Teva R&D was recognized as one of the 10 most exciting innovators in Pharma by IDEA Pharma and in 2017, Teva R&D ranked top of the industry for CNS development and clinical trial success by Pharma Intelligence.
Hayden is the most cited author in the world for Huntington disease and ABCA1, and has authored over 900 publications and invited submissions (Google Scholar citations 99,672, h-index 160, i10-index 766;[4] Web of Science citations 65,327, h-index 123).
In 2007, he received the Prix Galien which recognizes the outstanding contribution of a researcher to Canadian pharmaceutical research; in 2008, recognition from the Canadian Institutes of Health Research (CIHR) as Canada's Health Researcher of the Year: CIHR Michael Smith Prizes in Health Research.[5] In 2010, he was awarded Member of the Order of Canada,[6] following his receipt of the Order of British Columbia in 2009. Hayden received the Canada Gairdner Foundation Wightman Award[7] in 2011, recognizing him as a physician-scientist who has demonstrated outstanding leadership in medicine and medical science. He was inducted into the Canadian Medical Hall of Fame in 2017.[8] Most recently in 2020, Hayden was awarded the David Dubinsky Humanitarian Award from the American Friends of Soroka Medical Center (AFSMC). In addition to his academic work, Hayden is the co-founder of five biotechnology companies including: Prilenia, NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., Aspreva Pharmaceuticals Corp and 89Bio and the CEO of Prilenia Therapeutics. He currently sits on different public and private boards of biotechnologies companies.
- ^ a b Claudia Cornwall (Apr 1, 2008). "Michael Hayden: In The Genes". BCBusiness..
- ^ Teva Pharmaceutical Industries. (2012). "Dr. Michael Hayden". Teva Pharmaceutical Industries, Ltd. Archived from the original on 2012-08-23. Retrieved 2012-09-17.
- ^ George, John (21 July 2014). "Teva completes deal for second migraine-treatment developer". Phila. Bus. J. Retrieved 21 July 2014.
- ^ "Michael Hayden - Google Scholar Citations". scholar.google.ca. Retrieved 2017-03-31.
- ^ CIHR (2012). "Michael Hayden". Canadian Institutes of Health Research (CIHR). Archived from the original on 2013-03-19. Retrieved 2012-09-18.
- ^ Marie-Eve Letourneau (December 30, 2010). "Appointments to the Order of Canada". The Governor General of Canada. Retrieved 2011-05-12.
- ^ Gairdner Foundation (2011). "Michael Hayden". Canada Gairdner Foundation. Retrieved 2011-05-12.
- ^ "Induction Ceremony | Canadian Medical Hall of Fame". cdnmedhall.org. Retrieved 2017-03-31.